vs
Side-by-side financial comparison of MID PENN BANCORP INC (MPB) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
MID PENN BANCORP INC is the larger business by last-quarter revenue ($62.0M vs $34.1M, roughly 1.8× ZEVRA THERAPEUTICS, INC.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 30.8%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $5.5M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 21.1%).
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
MPB vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.0M | $34.1M |
| Net Profit | $19.4M | — |
| Gross Margin | — | — |
| Operating Margin | 43.6% | 27.3% |
| Net Margin | 31.4% | — |
| Revenue YoY | 30.8% | 183.4% |
| Net Profit YoY | 47.0% | — |
| EPS (diluted) | $0.83 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.0M | $34.1M | ||
| Q3 25 | $61.8M | $26.1M | ||
| Q2 25 | $54.3M | $25.9M | ||
| Q1 25 | $47.7M | $20.4M | ||
| Q4 24 | $47.4M | $12.0M | ||
| Q3 24 | $45.3M | $3.7M | ||
| Q2 24 | $44.1M | $4.4M | ||
| Q1 24 | $42.3M | $3.4M |
| Q4 25 | $19.4M | — | ||
| Q3 25 | $18.3M | $-544.0K | ||
| Q2 25 | $4.8M | $74.7M | ||
| Q1 25 | $13.7M | $-3.1M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $12.3M | $-33.2M | ||
| Q2 24 | $11.8M | $-19.9M | ||
| Q1 24 | $12.1M | $-16.6M |
| Q4 25 | 43.6% | 27.3% | ||
| Q3 25 | 39.3% | 15.9% | ||
| Q2 25 | 7.9% | -274.5% | ||
| Q1 25 | 35.2% | -26.3% | ||
| Q4 24 | 34.1% | -128.0% | ||
| Q3 24 | 32.8% | -739.0% | ||
| Q2 24 | 32.4% | -534.8% | ||
| Q1 24 | 34.8% | -598.1% |
| Q4 25 | 31.4% | — | ||
| Q3 25 | 29.6% | -2.1% | ||
| Q2 25 | 8.8% | 288.7% | ||
| Q1 25 | 28.8% | -15.2% | ||
| Q4 24 | 27.9% | — | ||
| Q3 24 | 27.1% | -899.2% | ||
| Q2 24 | 26.7% | -447.9% | ||
| Q1 24 | 28.7% | -485.3% |
| Q4 25 | $0.83 | — | ||
| Q3 25 | $0.79 | $-0.01 | ||
| Q2 25 | $0.22 | $1.21 | ||
| Q1 25 | $0.71 | — | ||
| Q4 24 | $0.72 | — | ||
| Q3 24 | $0.74 | $-0.69 | ||
| Q2 24 | $0.71 | $-0.48 | ||
| Q1 24 | $0.73 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $814.1M | $154.7M |
| Total Assets | $6.1B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $62.4M | ||
| Q3 25 | — | $54.4M | ||
| Q2 25 | — | $47.7M | ||
| Q1 25 | — | $37.3M | ||
| Q4 24 | — | $33.8M | ||
| Q3 24 | — | $54.0M | ||
| Q2 24 | — | $39.3M | ||
| Q1 24 | — | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $814.1M | $154.7M | ||
| Q3 25 | $796.3M | $133.2M | ||
| Q2 25 | $775.7M | $117.2M | ||
| Q1 25 | $667.9M | $41.0M | ||
| Q4 24 | $655.0M | $39.7M | ||
| Q3 24 | $573.1M | $69.8M | ||
| Q2 24 | $559.7M | $32.5M | ||
| Q1 24 | $551.0M | $48.8M |
| Q4 25 | $6.1B | $284.7M | ||
| Q3 25 | $6.3B | $270.1M | ||
| Q2 25 | $6.4B | $256.3M | ||
| Q1 25 | $5.5B | $172.7M | ||
| Q4 24 | $5.5B | $178.1M | ||
| Q3 24 | $5.5B | $191.6M | ||
| Q2 24 | $5.4B | $144.4M | ||
| Q1 24 | $5.3B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.0M | $5.5M |
| Free Cash FlowOCF − Capex | $71.8M | $5.5M |
| FCF MarginFCF / Revenue | 115.8% | 16.1% |
| Capex IntensityCapex / Revenue | 13.3% | 0.1% |
| Cash ConversionOCF / Net Profit | 4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $132.1M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.0M | $5.5M | ||
| Q3 25 | $26.3M | $4.7M | ||
| Q2 25 | $29.0M | $-3.6M | ||
| Q1 25 | $11.5M | $-8.2M | ||
| Q4 24 | $51.4M | $-16.3M | ||
| Q3 24 | $16.9M | $-18.1M | ||
| Q2 24 | $18.0M | $-19.1M | ||
| Q1 24 | $12.4M | $-16.2M |
| Q4 25 | $71.8M | $5.5M | ||
| Q3 25 | $24.3M | $4.2M | ||
| Q2 25 | $27.2M | $-3.8M | ||
| Q1 25 | $8.8M | $-8.3M | ||
| Q4 24 | $44.5M | — | ||
| Q3 24 | $16.8M | — | ||
| Q2 24 | $17.7M | — | ||
| Q1 24 | $12.1M | — |
| Q4 25 | 115.8% | 16.1% | ||
| Q3 25 | 39.4% | 15.9% | ||
| Q2 25 | 50.1% | -14.7% | ||
| Q1 25 | 18.4% | -40.8% | ||
| Q4 24 | 93.8% | — | ||
| Q3 24 | 37.1% | — | ||
| Q2 24 | 40.2% | — | ||
| Q1 24 | 28.5% | — |
| Q4 25 | 13.3% | 0.1% | ||
| Q3 25 | 3.1% | 2.1% | ||
| Q2 25 | 3.2% | 0.8% | ||
| Q1 25 | 5.7% | 0.5% | ||
| Q4 24 | 14.6% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% | ||
| Q1 24 | 0.8% | 0.0% |
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 6.08× | -0.05× | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MPB
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
